This week, I speak with Chris Burns, CEO of Amplia Therapeutics, a biotech company developing a promising FAK inhibitor for cancer treatment. Discover the science behind their approach, recent progress in clinical trials, and the vision for transforming pancreatic cancer outcomes.Key

Topics:

• The science behind FAK inhibitors and their role in modulating tumor microenvironments
• How Amplia's Narmaphonib improves efficacy, durability, and tolerability of pancreatic cancer treatments
• Strategic focus on FDA approval pathway and ongoing clinical trials in the US and Australia
• The significance of combination therapies in overcoming resistance and enhancing effectiveness
• The future potential of FAK inhibitors in treating other solid tumors like ovarian and lung cancer
• Chris Burns' journey from academic research in Australia to biotech leadership and innovation

Amplia Therapeutics Website: https://ampliatx.com/

Nano Cap Podcast Website https://www.nanocappod.com/

DISCLAIMER - The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.